Sarepta Therapeutics (SRPT) Competitors $17.93 -0.72 (-3.86%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$18.54 +0.61 (+3.37%) As of 05:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRPT vs. CTMX, EDIT, GRFS, ABVX, RYTM, LEGN, CYTK, AXSM, NUVL, and CRSPShould you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Grifols (GRFS), Abivax (ABVX), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Cytokinetics (CYTK), Axsome Therapeutics (AXSM), Nuvalent (NUVL), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Sarepta Therapeutics vs. Its Competitors CytomX Therapeutics Editas Medicine Grifols Abivax Rhythm Pharmaceuticals Legend Biotech Cytokinetics Axsome Therapeutics Nuvalent CRISPR Therapeutics Sarepta Therapeutics (NASDAQ:SRPT) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Which has better valuation and earnings, SRPT or CTMX? Sarepta Therapeutics has higher revenue and earnings than CytomX Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$2.48B0.71$235.24M-$0.87-20.61CytomX Therapeutics$138.10M2.52$31.87M$0.563.77 Which has more risk and volatility, SRPT or CTMX? Sarepta Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Does the media favor SRPT or CTMX? In the previous week, CytomX Therapeutics had 11 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 19 mentions for CytomX Therapeutics and 8 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.78 beat CytomX Therapeutics' score of 0.53 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in SRPT or CTMX? 86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 7.6% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is SRPT or CTMX more profitable? CytomX Therapeutics has a net margin of 34.04% compared to Sarepta Therapeutics' net margin of -2.34%. CytomX Therapeutics' return on equity of 158.70% beat Sarepta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics-2.34% -1.03% -0.37% CytomX Therapeutics 34.04%158.70%36.04% Do analysts prefer SRPT or CTMX? Sarepta Therapeutics currently has a consensus price target of $39.32, indicating a potential upside of 119.30%. CytomX Therapeutics has a consensus price target of $5.42, indicating a potential upside of 156.71%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 6 Sell rating(s) 14 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.10CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryCytomX Therapeutics beats Sarepta Therapeutics on 11 of the 17 factors compared between the two stocks. Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRPT vs. The Competition Export to ExcelMetricSarepta TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.82B$3.16B$5.76B$10.51BDividend YieldN/A2.36%5.53%4.57%P/E Ratio-20.6121.0476.0626.61Price / Sales0.71252.06472.8291.51Price / Cash7.6646.3537.4661.85Price / Book1.129.7813.586.45Net Income$235.24M-$52.73M$3.29B$271.57M7 Day Performance5.16%3.16%1.83%2.61%1 Month Performance-11.33%4.69%4.02%7.28%1 Year Performance-85.71%16.37%77.05%29.60% Sarepta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRPTSarepta Therapeutics4.3468 of 5 stars$17.93-3.9%$39.32+119.3%-85.6%$1.82B$2.48B-20.611,372Analyst UpgradeGap UpCTMXCytomX Therapeutics4.2069 of 5 stars$1.99-0.5%$5.75+188.9%+83.5%$328.17M$138.10M3.55170News CoverageAnalyst ForecastAnalyst RevisionEDITEditas Medicine3.8637 of 5 stars$2.67-0.7%$5.10+91.0%-17.8%$240.09M$32.31M-0.94230GRFSGrifols3.9122 of 5 stars$9.63-2.5%$10.30+7.0%+11.9%$6.62B$7.45B8.2323,822Positive NewsGap UpABVXAbivax2.8083 of 5 stars$85.87+2.2%$99.43+15.8%+655.2%$6.49BN/A0.0061RYTMRhythm Pharmaceuticals3.206 of 5 stars$96.03-0.2%$101.57+5.8%+93.3%$6.38B$130.13M-31.90140Positive NewsLEGNLegend Biotech3.1544 of 5 stars$33.88+2.3%$74.22+119.1%-28.3%$6.25B$627.24M-38.502,609Positive NewsCYTKCytokinetics4.2401 of 5 stars$49.44-3.3%$75.38+52.5%-6.8%$5.92B$18.47M-9.69250Trending NewsAnalyst ForecastAXSMAxsome Therapeutics4.849 of 5 stars$116.78-1.4%$177.86+52.3%+29.1%$5.83B$385.69M-23.03380Insider TradeNUVLNuvalent2.9686 of 5 stars$79.37-1.4%$120.91+52.3%-20.5%$5.72BN/A-16.2040CRSPCRISPR Therapeutics3.2349 of 5 stars$57.84+2.8%$71.60+23.8%+30.0%$5.26B$37.31M-10.65460Analyst Forecast Related Companies and Tools Related Companies CytomX Therapeutics Competitors Editas Medicine Competitors Grifols Competitors Abivax Competitors Rhythm Pharmaceuticals Competitors Legend Biotech Competitors Cytokinetics Competitors Axsome Therapeutics Competitors Nuvalent Competitors CRISPR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRPT) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
